TimestampsSpeaker 1: (01:17) Can you tell us why that decision was made and how you went about bringing up this new test? Speaker 1: (04:27) We went with our laboratory developed test, which was essential to get us up and running, but had a limited throughput. Then you've basically tripled our capacity by adding these additional platforms and tests.Speaker 1: (05:27) Now I also know when you verified this, you really turned it around amazingly fast. Can you tell us a bit about that? Speaker 1: (06:46) That is amazing. Now you mentioned the assay has received EUA—emergency use authorization—from the Food and Drug Administration or FDA. Now what specimens does this assay have EUA for? Speaker 1: (07:31) Are you adding additional specimen types to what you're accepting for this assay? Speaker 1: (09:23) How are you using this assay today and what is your total capacity for testing? Speaker 1: (11:41) Now you've also brought in another test. How was that decision made and do you want to tell us a little bit about that? Speaker 1: (14:34) Now, I don't believe before this that you were working 24/7, is that correct? Resources:https://news.mayocliniclabs.com/covid19/

Ver todos los episodios